Anqing Wu

Dr. Anqing Wu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AWAnqing Wu
Anqing Wu
JTJiaxin Tang Tang
Jiaxin Tang Tang
ZGZiyang Guo
Ziyang Guo
YDYingchu Dai
Yingchu Dai
JNJing Nie
Jing Nie
GZGuangming Zhou
Guangming Zhou
The occurrence of distant tumor metastases is a major barrier in non-small cell lung cancer (NSCLC) therapy, and seriously affects clinical treatment and patient prognosis. Recently, long non-coding RNAs (lncRNAs) have been demonstrated to be crucial regulators of metastasis in lung cancer. The aim of this study was to reveal the underlying mechanisms of a novel lncRNA LNC CRYBG3 in regulating NSCLC metastasis. Experimental results showed that LNC CRYBG3 was upregulated in NSCLC cells compared with normal tissue cells, and its level was involved in these cells’ metastatic ability. Exogenously overexpressed LNC CRYBG3 increased the metastatic ability and the protein expression level of the metastasis-associated proteins Snail and Vimentin in low metastatic lung cancer HCC827 cell line. In addition, LNC CRYBG3 contributed to HCC827 cell metastasis in vivo. Mechanistically, LNC CRYBG3 could directly combine with eEF1A1 and promote it to move into the nucleus to enhance the transcription of MDM2. Overexpressed MDM2 combined with MDM2 binding protein (MTBP) to reduce the binding of MTBP with ACTN4 and consequently increased cell migration mediated by ACTN4. In conclusion, the LNC CRYBG3/eEF1A1/MDM2/MTBP axis is a novel signaling pathway regulating tumor metastasis and may be a potential therapeutic target for NSCLC treatment.

22 May 2025 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
SLShanghai Liu
Shanghai Liu
XHXiangyang He
Xiangyang He
SLSiqi Liang
Siqi Liang
AWAnqing Wu
Anqing Wu
LLLu Liu
Lu Liu
Wentao HuWentao Hu
Wentao Hu
Carbon ion radiotherapy (CIRT), a type of particle therapy, is at the forefront of clinical oncology treatments due to its superior physical properties and biological performance. Although CIRT has demonstrated outstanding therapeutic outcomes in clinical settings, the biological mechanisms underpinning its effects, particularly its immunogenic potential and the superiority of its induced antitumor immune response compared to photon radiotherapy, remain areas of active investigation. This review summarizes the latest research progress on the mechanisms of antitumor immune responses triggered by CIRT and discusses preclinical and clinical studies related to combined CIRT and immunotherapy (CCIT). Against the backdrop of extensive research and significant clinical efficacy achieved by combining radiotherapy with immunotherapy, this review provides a theoretical foundation for a better understanding of the superior tumor cell-killing effects of CIRT and the underlying immunological mechanisms. Further insights into the factors affecting the efficacy, toxic effects, and developmental limitations of this combination therapy mode will be instrumental in guiding the conduction of CCIT studies.

4 September 2023 in Biology
Verified
Journal Article
Open access
PDF file
HTHaoyi Tang
Haoyi Tang
SLShanghai Liu
Shanghai Liu
XYXiangyu Yan
Xiangyu Yan
YJYusheng Jin
Yusheng Jin
XHXiangyang He
Xiangyang He
AWAnqing Wu
Anqing Wu
Lung cancer remains the leading cause of cancer-related deaths in both women and men, claiming millions of lives worldwide. Radiotherapy is an effective modality for treating early-stage lung cancer; however, it cannot completely eradicate certain tumor cells due to their radioresistance. Radioresistance is commonly observed in conventionally fractionated radiotherapy, which can lead to treatment failure, metastasis, cancer recurrence, and poor prognosis for cancer patients. Identifying the underlying molecular mechanisms of radioresistance in lung cancer can promote the development of effective radiosensitizers, thereby improving patients’ life expectancy and curability. In this study, we identified LNC EBLN3P as a regulator of lung cancer cell proliferation and radiosensitivity. The repression of LNC EBLN3P could increase ROS production and mitochondrial injury in NSCLC cells. In addition, knocking down LNC EBLN3P increased the binding of Nrf2 to Keap1, resulting in enhanced Nrf2 degradation, decreased translocation of Nrf2 to the nucleus, reduced expression of antioxidant protein HO-1, weakened cellular antioxidant capacity, and increased radiosensitivity of NSCLC cells. These findings suggest that targeting LNC EBLN3P could be a promising strategy for developing novel radiosensitizers in the context of conventional radiotherapy for NSCLC.

1 January 2025 in BIOCELL
Verified
Journal Article
Open access
PDF file
XYXiangyu Yan
Xiangyu Yan
YJYusheng Jin
Yusheng Jin
YYYan Yuan
Yan Yuan
XZXubaihe Zhang
Xubaihe Zhang
JLJiayi Li
Jiayi Li
AWAnqing Wu
Anqing Wu
Objectives: Fractionated radiotherapy represents a standardized and widely adopted treatment modality for cancer management, with approximately 40% of non-small cell lung cancer (NSCLC) patients receiving it. However, repeated irradiation may induce radioresistance in cancer cells, reducing treatment effectiveness and raising recurrence risk. The long noncoding RNA CRYBG3 (lncRNA CRYBG3), which is upregulated in lung cancer cells after X-ray irradiation, contributes to the radioresistance of NSCLC cells by promoting wild-type p53 protein degradation. This study aims to elucidate the mechanism of fractionated irradiation-induced radioresistance, in which lncRNA CRYBG3 regulates radiation-induced mitochondrial damage and reactive oxygen species (ROS) generation through the p53 downstream signaling pathway. Methods: To investigate the critical roles of lncRNA CRYBG3 in mediating radioresistance induced by fractionated irradiation in NSCLC, we established radioresistant NSCLC cells by irradiating the A549 and H460 cell lines with 60 Gy of X-rays in 12 fractions, and named the radioresistant cells A549R and H460R, respectively. Lentiviral vectors were used to deliver short hairpin RNA (shRNA) into cells to knock down lncRNA CRYBG3, thereby investigating its contribution to adaptive radioresistance in A549R and H460R cells. All cells were irradiated with 4 Gy of X-rays, and subsequent analyses were conducted to evaluate mitochondrial damage, ROS generation, apoptosis, and the expression of oxidative stress-related proteins. Results: Increased expression levels of lncRNA CRYBG3 were positively associated with the acquisition of radioresistance in NSCLC cells. Additionally, suppressing lncRNA CRYBG3 increased mitochondrial damage and promoted radiation-induced apoptosis in radioresistant NSCLC cells. Mechanistically, the downregulation of lncRNA CRYBG3 led to increased p53 levels, resulting in decreased expression of heat shock factor 1 (HSF1) and tumor necrosis factor receptor-associated protein 1 (TRAP1), as well as enhanced radiation-induced mitochondrial oxidative damage and apoptosis. Conclusion: The results indicate that lncRNA CRYBG3 plays a regulatory role in adaptive radioresistance in NSCLC cells through the p53/HSF1/TRAP1 axis. Therefore, targeting lncRNA CRYBG3 could potentially improve the efficacy of fractionated radiotherapy in NSCLC.